Search
Researchers from MSK presented promising studies on treating rare solid tumors including mesothelioma and three types of soft-tissue at the annual meeting of the American Society of Clinical Oncology.
Learn how a new cancer engineering PhD program is attracting leading scientists to come to MSK.
Following an approval from the FDA in May 2020, the New England Journal of Medicine has published data from the phase I/II LIBRETTO-001 clinical trial of selpercatinib in advanced RET (REarranged during Transfection)-driven lung and thyroid cancers. MSK’s Alexander Drilon, MD, the recently appointed Chief of the Early Drug Development Service, serves as the lead investigator for multi-site clinical trial.
Two intraperitoneal chemotherapy approaches are being compared for effectiveness and toxicity in Memorial Sloan Kettering Cancer Center’s phase II clinical trial, which continues to enroll cytoreductive cancer surgery patients with isolated peritoneal metastasis.
Paige Arnold, who will graduate from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) next spring, has been awarded the 2022 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Emeritus Louis V. Gerstner, Jr., for whom the school is named.
A new drug delivery method could improve treatment of a lethal pediatric brain tumor called diffuse intrinsic pontine glioma.
The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general.
Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA (mRNA) can inactivate the functions of tumor suppressor genes and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease, indicating that cancer diagnostics need to go beyond the analysis of DNA mutations.
Receiving five or more cycles of neoadjuvant chemotherapy was associated with worse progression-free survival (PFS) and overall survival (OS) compared to receiving three or four cycles — despite maximal surgical cytoreduction.
On June 7 when Memorial Sloan Kettering opened a facility housing the novel Center for Image-Guided Interventions, a suite of endoscopy rooms, and new operating rooms for the Surgical Day Hospital.